Table 4.
Validation on 4 of the significant EGF SNPs in a data set of 638 glioblastoma cases recruited at MDACC, from 18 years of age, recruited from 1990 to 2008, with follow-up until April 2009
| Region | Major allele | Genotype | No. (%) | HR (95% CI) | P value | Median survival time | |
|---|---|---|---|---|---|---|---|
| rs17238095 | Promoter region | C | CC | 319 (54.1) | 1.0 | 24.1 | |
| CT | 230 (39.0) | 1.09 (0.93–1.31) | .632 | 23.4 | |||
| TT | 41 (6.9) | 1.28 (0.93–1.77) | .163 | 17.2 | |||
| rs3796944 | Intron 5 | A | AA | 200 (33.9) | 1.0 | 24.5 | |
| AG | 284 (48.1) | 1.09 (0.91–1.32) | .446 | 23.8 | |||
| GG | 106 (18.0) | 1.19 (0.94–1.51) | .231 | 18.6 | |||
| rs9992755 | Intron 7 | A | AA | 252 (42.7) | 1.0 | 24.1 | |
| AG | 272 (46.1) | 1.09 (0.90–1.28) | .561 | 23.1 | |||
| GG | 66 (11.2) | 1.06 (0.81–1.38) | .881 | 19.6 | |||
| rs11568994 | Intron 13 | G | GG | 251 (42.5) | 1.0 | 24.2 | |
| AG | 274 (46.4) | 1.16 (0.88–1.53) | .342 | 23.5 | |||
| AA | 65 (11.0) | 1.05 (0.87–1.25) | .876 | 18.1 |
All hazard ratios (HRs) are adjusted for sex and age.